Articles tagged "Post-transplant lymphoproliferative disorder (PTLD)"

2019 American Transplant Congress
Phylogenetic Analysis of the Epstein Barr Virus Nuclear Antigen-1 and Associated Correlates among Canadian Transplant Patients
M. Abdulnoor¹, S. Isabel¹, T. Paton¹, N. Khodai-Booran¹, T. Schechter¹, P. Birk², T. Blydt-Hansen³, B. Foster⁴, S. Mital¹, V. Phan⁵, S. Urschel⁶, G. Casallo¹, T. Papaz¹, L. Hamiwka⁷, S. Min¹, U. Allen¹
¹University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Montreal, Montreal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada
*Purpose: The effect of the genetic diversity of the Epstein-Barr virus (EBV) on clinical outcomes in the transplant setting is important to study. We examined…
2019 American Transplant Congress
Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?
A. Jagdale¹, H. Iwase¹, E. Klein², D. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…
2019 American Transplant Congress
EBV⁺ PTLD Cell Lines Secrete Exosomes Containing microRNAs That Alter Immune Responses
S. Syed, E. Maloney, A. Hui, O. Martinez, S. Krams
Stanford Univ School of Med, Stanford, CA
*Purpose: Exosomes are nanometric (50-150nm) membrane vesicles that are released, into blood and other body fluids, by most cell types. Exosomes, which are generated from…
2019 American Transplant Congress
Steadily Dropping Malignancy Rates after Pediatric Kidney Transplantation Have Now Reversed in the Most Recent Era: A Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
V. Dharnidharka¹, C. Cramer², A. Chua³, A. Moudgil⁴, K. Martz⁵, T. Blydt-Hansen⁶, J. Smith⁷, A. Neu, on behalf of the NAPRTCS Investigators⁸
¹Washington University in St. Louis, Saint Louis, MO, ²Mayo Clinic, Rochester, MN, ³Duke University, Durham, NC, ⁴Children's National Medical Center, Washington, DC, ⁵Emmes Corporation, Rockville, MD, ⁶BC Children's Hospital, Vancouver, BC, Canada, ⁷Seattle Children's Hospital, Seattle, WA, ⁸Johns Hopkins University, Baltimore, MD
*Purpose: In general, malignancies are very rare in children, compared to older adults. The NAPRTCS registry has collected data on children receiving kidney transplants in…
2019 American Transplant Congress
Epstein Barr Virus DNA Integration in B Cell Lymphomas of Post-Transplant Lymphoproliferative Disorder
M. C. McPherson, O. M. Martinez
Surgery, Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA
*Purpose: Epstein Barr virus-positive (EBV+) B cell lymphomas can arise in immunosuppressed individuals, such as organ transplant recipients in the context of post-transplant lymphoproliferative disorder…
2019 American Transplant Congress
Post-transplant Lymphoproliferative Disorder Following Intestine Transplantation: Contemporary Single Center Experience
A. Zimmerman, J. Hawksworth, A. Kroemer, P. Radkani, K. Khan, S. Kaufman, N. Yazigi, S. Subramanian, T. Fishbein, C. Matsumoto
Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC
*Purpose: The purpose of this study was to examine the characteristics and risk factors for PTLD after intestinal transplant.*Methods: Retrospective review of intestinal transplant recipients…
2019 American Transplant Congress
EBV+ PTLD in the Modern Immunosuppression Era: Role of EBV Serology and DNAemia-Preliminary Data from CTOT-C06
O. M. Martinez¹, S. M. Krams¹, M. A. Robien², M. Lapasaran¹, S. D. Boyd¹, B. Armstrong³, C. Twist⁴, K. Weinberg¹, D. Gratzinger¹, B. Tan¹, M. Sever³, D. Ikle³, M. Brown², D. Bernstein¹, C. O. Esquivel¹
¹Stanford University Sch of Med, Stanford, CA, ²NIAID/NIH, Rockville, MD, ³Rho, Chapel Hill, NC, ⁴Roswell Park, Buffalo, NY
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is an…
2018 American Transplant Congress
Presentation and Outcomes of Post-Transplant Proliferative Disorder at a Single Institution Pediatric Transplant Center
G. Ramos-Gonzalez,¹ A. Allain,¹ T. Agur,¹ L. O'Melia,¹ S. Staffa,² S. Burchett,¹ B. Siegele,³ O. Weinberg,³ N. Rodig,¹ R. Fawaz,¹ T. Singh,¹ D. Freiberger,¹ K. Heung Bae.¹
¹Pediatric Transplant Center, Boston Children's Hospital, Boston, MA; ²Department of Surgery, Boston Children's Hospital, Boston, MA; ³Department of Pathology, Boston Children's Hospital, Boston, MA.
Purpose: The aim of this study was to characterize features present at the time of post-transplant lymphoproliferative disorder (PTLD) diagnosis, as well as outcomes, following…
2018 American Transplant Congress
Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation: A Single Institute Experience with Focus on Epstein-Barr Virus Status
P. Zhang,¹ R. King,¹ K. Ristow,² L. Cornell,¹ F. Cosio,³ T. Habermann,² M. Alexander.¹
¹Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ²Divsion of Hematology and Oncology, Mayo Clinic, Rochester, MN; ³Divsion of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Background: Comparing to other types of solid organ transplant, the Post-Transplant Lymphopro- liferative Disorder (PTLD) in kidney transplant recipients (KTRs) is relatively rare. Due to…
2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
P. Chen,² L. Nair,² A. Ata,² D. Conti,¹ R. Lopez-Soler.¹
¹Surgery, Section of Transplantation, Albany Medical College, Albany, NY; ²Surgery, Albany Medical College, Albany, NY.
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…